851 related articles for article (PubMed ID: 26981025)
1. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
Caviglia GP; Cabianca L; Fagoonee S; Gili FM
Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
[TBL] [Abstract][Full Text] [Related]
2. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
[TBL] [Abstract][Full Text] [Related]
3. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
[TBL] [Abstract][Full Text] [Related]
4. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
[TBL] [Abstract][Full Text] [Related]
5. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
[TBL] [Abstract][Full Text] [Related]
6. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program.
Chiang TH; Chuang SL; Chen SL; Chiu HM; Yen AM; Chiu SY; Fann JC; Chou CK; Lee YC; Wu MS; Chen HH
Gastroenterology; 2014 Dec; 147(6):1317-26. PubMed ID: 25200099
[TBL] [Abstract][Full Text] [Related]
7. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
[TBL] [Abstract][Full Text] [Related]
8. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
[TBL] [Abstract][Full Text] [Related]
9. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
[TBL] [Abstract][Full Text] [Related]
10. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Performance of a Fecal Tumor M2-PK Rapid Kit Using Stool Specimens for Detection of Colorectal Tumors.
Cho CH; Kim J; Jang MA; Lee BJ; Park JJ; Lim CS
Ann Clin Lab Sci; 2016; 46(2):154-60. PubMed ID: 27098621
[TBL] [Abstract][Full Text] [Related]
12. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
[TBL] [Abstract][Full Text] [Related]
13. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
[TBL] [Abstract][Full Text] [Related]
14. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
15. A quantitative immunochemical fecal occult blood test for colorectal neoplasia.
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Leshno M; Niv Y
Ann Intern Med; 2007 Feb; 146(4):244-55. PubMed ID: 17310048
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.
Tonus C; Neupert G; Sellinger M
World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496
[TBL] [Abstract][Full Text] [Related]
18. Controversies in colorectal cancer screening.
Pox CP
Digestion; 2014; 89(4):274-81. PubMed ID: 25034478
[TBL] [Abstract][Full Text] [Related]
19. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
